Clinical and clinicopathological features and outcomes of cats with suspected dietary induced pancytopenia.

Background: After a strong epidemiological link to diet was established in an outbreak of pancytopenia in cats in spring 2021 in the United Kingdom, 3 dry diets were recalled. Concentrations of the hemato- and myelotoxic mycotoxins T-2, HT-2 and diacetoxyscirpenol (DAS) greater than the European Commission guidance for dry cat foods were detected in the recalled diets.

Objectives: To describe clinical and clinicopathological findings in cats diagnosed with suspected diet induced pancytopenia.

Isolation of dermatophytes from dogs and cats in the South of England between 1991 and 2017.

Background: Since the epidemiology of canine and feline dermatophytosis might evolve in response to chronological, sociological and ecological factors, the authors studied the occurrence of dermatophyte pathogens over 27 years subsequent to the last major UK survey.

Methods: Dermatophyte culture submission records from dogs and cats to the Royal Veterinary College Diagnostic Laboratory in England between 1991 and 2017 were reviewed. Samples were routinely cultured aerobically at 26°C for up to four weeks on Sabouraud's dextrose agar containing cycloheximide and chloramphenicol; dermatophytes were identified using conventional phenotypic methods.

Population Pharmacokinetics of Amikacin in Adult Patients with Cystic Fibrosis.

Practitioners commonly use amikacin in patients with cystic fibrosis. Establishment of the pharmacokinetics of amikacin in adults with cystic fibrosis may increase the efficacy and safety of therapy. This study was aimed to establish the population pharmacokinetics of amikacin in adults with cystic fibrosis.

Sputum biomarkers and the prediction of clinical outcomes in patients with cystic fibrosis.

Lung function, acute pulmonary exacerbations (APE), and weight are the best clinical predictors of survival in cystic fibrosis (CF); however, underlying mechanisms are incompletely understood. Biomarkers of current disease state predictive of future outcomes might identify mechanisms and provide treatment targets, trial endpoints and objective clinical monitoring tools. Such CF-specific biomarkers have previously been elusive.